Attached To Antibody Or Antibody Fragment Or Immunoglobulin; Derivative Patents (Class 424/1.49)
-
Publication number: 20110150765Abstract: Certain embodiments disclosed herein relate to compositions, methods, devices, systems, and products regarding frozen particles. In certain embodiments, the frozen particles include materials at low temperatures. In certain embodiments, the frozen particles provide vehicles for delivery of particular agents. In certain embodiments, the frozen particles are administered to at least one biological tissue.Type: ApplicationFiled: September 15, 2009Publication date: June 23, 2011Inventors: Edward S. Boyden, Daniel B. Cook, Roderick A. Hyde, Eric C. Leuthardt, Nathan P. Myhrvold, Elizabeth A. Sweeney, Lowell L. Wood, JR.
-
Publication number: 20110150759Abstract: The present invention relates to antibodies, particularly antibody 175, and fragments thereof or antibodies derived therefrom, which bind to the EGF receptor, particularly to amplified or overexpressed epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. These antibodies are useful in the diagnosis and treatment of cancer. Recombinant or hybrid antibodies having the variable region heavy or light chain sequence(s) of antibody 175 are also provided. The antibodies of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.Type: ApplicationFiled: August 14, 2008Publication date: June 23, 2011Inventors: Terrance Grant Johns, Elizabeth Stockert, Stephan Stockert, Lioyd J. Old
-
Publication number: 20110135570Abstract: Methods of diagnosing, detecting or treating cancer where the cancer expresses a tumor cell antigen that is elevated relative to the normal adjacent tissue, by administering an antibody or antibody fragment which binds to that tumor cell antigen. The methods involve the use of antibodies that bind to the tumor cell antigens KIAA1815, LOC157378, FU20421, DSCD75, GPR160, GPCR41, and SLC1A5.Type: ApplicationFiled: March 22, 2007Publication date: June 9, 2011Inventors: Mary Jo Janatpour, Guoying K. Yu
-
Patent number: 7955590Abstract: Disclosed herein are methods and compositions for enhancing the immunogenicity of a preselected protein or peptide antigen in a mammal. Immunogenicity is enhanced by fusing the preselected antigen to an immunoglobulin heavy chain constant region to produce an Fc-antigen fusion protein. The Fc-antigen fusion proteins bind Fc receptors on the surface of antigen presenting cells, thereby targeting the antigen to the antigen presenting cells in the mammal. In addition, disclosed is a family of adjuvants, for example, an Fc-adjuvant fusion protein, for use in combination with the Fc-antigen fusion proteins to enhance or modulate a particular immune response against the preselected antigen.Type: GrantFiled: March 24, 2005Date of Patent: June 7, 2011Assignee: Merck Patent GmbHInventors: Stephen D. Gillies, Kin-Ming Lo, John S. Wesolowski, Jr.
-
Publication number: 20110129416Abstract: The present invention provides for recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens, along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to the nucleic acids, and uses for these antibodies, nucleic acids and amino acids.Type: ApplicationFiled: January 24, 2011Publication date: June 2, 2011Applicant: NEOGENIX ONCOLOGY, INC.Inventors: J. Andrew BRISTOL, Judith A. Kantor
-
Publication number: 20110129414Abstract: Anti-ACE single chain fragment antibodies are disclosed. The present invention relates to using these antibodies, and polymers thereof, in methods for detecting, diagnosing, prognosing, preventing, or treating diseases associated with ACE expressing tissue.Type: ApplicationFiled: November 15, 2006Publication date: June 2, 2011Inventors: Irina V. Balyasnikova, Sergei M. Danilov
-
Publication number: 20110129415Abstract: The present invention provides a composition comprising an antibody or fragment thereof against oxidised Collagen II (CII) in which the antibody or fragment thereof is conjugated to a pharmaceutically active moiety. The invention also provides a composition comprising an antibody or fragment thereof against oxidised Collagen II (Gil) and a detectable label. The invention further provides the use of such compositions in medicine, in particular for the treatment of an arthropathy, and in methods of diagnosis.Type: ApplicationFiled: May 2, 2008Publication date: June 2, 2011Inventors: Ahuva Nissim, Yuti Chernajovsky, Bjarne Faurholm, David Perrett, Paul Winyard, Christopher Hughes, Stephen Mather, Francesco Dell'Accio
-
Patent number: 7951356Abstract: The invention embodies the surprising discovery that Tissue Factor (TF) compositions and variants thereof specifically localize to the blood vessels within a vascularized tumor following systemic administration. The invention therefore provides methods and compositions comprising coagulant-deficient Tissue Factor for use in effecting specific coagulation and for use in tumor treatment. The TF compositions and methods of present invention may be used alone, as TF conjugates with improved half-life, or in combination with other agents, such as conventional chemotherapeutic drugs, targeted immunotoxins, targeted coaguligands, and/or in combination with Factor VIIa (FVIIa) or FVIIa activators.Type: GrantFiled: May 18, 2000Date of Patent: May 31, 2011Assignee: Board of Regents, The University of Texas SystemInventors: Philip E. Thorpe, Steven W. King, Boning Gao
-
Publication number: 20110123442Abstract: Provided are isolated antibodies, and fragments and derivatives thereof, which bind to tumor antigens. Also provided are compositions and delivery agents that include the disclosed antibodies and fragments and derivatives thereof; cells that produce the same; methods for producing the same; methods of using the same for detecting, targeting, and/or treating tumors and/or metastatic cells derived therefrom and/or tumor stem cells; and methods for predicting the recurrence of cancer in a subject.Type: ApplicationFiled: October 8, 2010Publication date: May 26, 2011Inventor: Pinku Mukherjee
-
Publication number: 20110123440Abstract: The present invention relates to altered antibody Fc regions and uses thereof.Type: ApplicationFiled: March 28, 2006Publication date: May 26, 2011Inventors: Genevieve Hansen, Gerald Neslund, Amelia Black, Josephine M. Cardarelli, Srinivasan Mohan, David J. King
-
Publication number: 20110123443Abstract: A biomarker for pancreatic beta-cell mass comprising measuring the levels of CFC1 in the serum of a subject is described. The biomarker provides a noninvasive means for measuring pancreatic beta cell mass that is particularly useful for monitoring the efficacy of treatments for metabolic disorders such as Type I or Type II diabetes, including pancreatic islet cell transplantations.Type: ApplicationFiled: April 10, 2009Publication date: May 26, 2011Applicant: MERCK & CO., INC.Inventors: Yun-Ping Zhou, Andrew Howard, Nancy Thornberry
-
Publication number: 20110123444Abstract: The invention relates to the use of a radioactively labelled molecule specifically binding to ED-B fibronectin in a method of treatment for patients with Hodgkin lymphoma, in particular primary refractory Hodgkin lymphoma or recurrent Hodgkin lymphoma after chemotherapy, and for Hodgkin lymphoma patients scheduled for primary combined-modality therapy.Type: ApplicationFiled: May 2, 2009Publication date: May 26, 2011Applicant: Bayer Schering Pharma AktiengesellschaftInventors: Hans Dietrich Menssen, Jörg Pinkert
-
Publication number: 20110123441Abstract: The generation and validation of a novel monoclonal GREB1 antibody (GREB1ab). Methods for the prognosis, diagnosis, assessment of disease progression, severity and outcome utilize GREB1 molecules as biomarkers. The GREB1 antibody is also a useful tool for investigations focused on the expression, distribution and function of GREB1 in normal and cancer tissues.Type: ApplicationFiled: October 20, 2010Publication date: May 26, 2011Applicants: UNIVERSITY OF MIAMI, THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Marc E. Lippman, Harry James Hnatyszyn, Mingli Liu, James M. Rae
-
Publication number: 20110117013Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.Type: ApplicationFiled: June 8, 2010Publication date: May 19, 2011Applicant: FACET BIOTECH CORPORATIONInventors: David Mack, Kurt C. Gish
-
Publication number: 20110110852Abstract: The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies.Type: ApplicationFiled: November 3, 2010Publication date: May 12, 2011Applicant: Genentech, Inc.Inventors: Kathy L. Miller, Leonard G. Presta
-
Publication number: 20110110854Abstract: The present application discloses compositions and methods of synthesis and use of 68Ga, 18F or 19F labeled molecules of use in PET or MRI imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a chelating moiety, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 68Ga, 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. In more preferred embodiments, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment.Type: ApplicationFiled: December 2, 2010Publication date: May 12, 2011Applicant: IMMUNOMEDICS, INC.Inventors: William J. McBride, Christopher A. D'Souza, David M. Goldenberg
-
Publication number: 20110110853Abstract: Described herein are isolated mammalian cells (progenitor cell biomarkers), referred to as primitive vascular progenitor cells (PVPC), which are present in and isolated from blood (e.g., peripheral blood) and useful as biomarkers of vascular remodeling in mammals (e.g., humans, rodents).Type: ApplicationFiled: June 30, 2009Publication date: May 12, 2011Applicant: UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORKInventor: Noel Caplice
-
Publication number: 20110104053Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca++ signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed.Type: ApplicationFiled: July 29, 2010Publication date: May 5, 2011Inventors: Moses Rodriguez, David J. Miller, Larry R. Pease
-
Publication number: 20110097261Abstract: The invention provides, inter alia, methods for treating cancer, compositions for treating cancer, and methods and compositions for diagnosing and/or detecting cancer. In particular, the present invention provides compositions and methods for treating, diagnosing and detecting cancers associated with AMIGO-2 overexpression.Type: ApplicationFiled: July 19, 2007Publication date: April 28, 2011Inventor: Mary J. Janatpour
-
Publication number: 20110097262Abstract: The invention relates to a novel antibody capable of binding specifically to the human c-Met receptor and/or capable of specifically inhibiting the tyrosine kinase activity of said receptor both in a ligand-dependent and in a ligand-independent manner, with an improved antagonistic activity, said antibody comprising a modified hinge region. The invention also relates to a composition comprising such an antibody antagonist to c-Met and its use as a medicament for treating cancer.Type: ApplicationFiled: June 1, 2010Publication date: April 28, 2011Inventors: Liliane Goetsch, Thierry Wurch, Cédric Bes
-
Patent number: 7931890Abstract: The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities, and wherein the therapeutic agents are delivered to the tumor sites using combined targeting and pre-targeting methods. The methods of the present invention achieve good tumor to non-tumor ratios of the therapeutic agents, and are effective for cancer therapy.Type: GrantFiled: August 25, 2005Date of Patent: April 26, 2011Assignee: Immunomedics, Inc.Inventors: Gary L. Griffiths, Hans J. Hansen, David M. Goldenberg
-
Publication number: 20110091463Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: ApplicationFiled: October 15, 2010Publication date: April 21, 2011Applicant: ABBOTT LABORATORIESInventors: Tariq Ghayur, Rajesh V. Kamath, Junian Liu, Marie P. Honore
-
Publication number: 20110091379Abstract: The invention relates to a medicament against tumors and their metastases, which preferentially settle in bone tissue, comprising active ingredient at least one binding molecule that binds to bone sialoprotein or a fragment thereof in serum or plasma.Type: ApplicationFiled: October 8, 2010Publication date: April 21, 2011Applicant: ARMBRUSTER BIOTECHNOLOGY GMBHInventors: Franz Paul ARMBRUSTER, Markus Karmatschek, Franz Werner Nader, Ulf Joerg Forssmann, Mats Paulsson, Martin R. Berger
-
Publication number: 20110091378Abstract: The present invention relates methods and compositions for treating interleukin-17 (IL-17) related conditions, such as IL-17A or IL-17F, or muteins thereof in patients having fibrosis using IL-17 antagonists, such as small molecule IL-17 antagonists or protein IL-17 antagonists, such as antibodies, including specified portions or variants, specific for at least one IL-17 protein, mutein or fragment thereof, including therapeutic formulations, administration and devices.Type: ApplicationFiled: July 21, 2008Publication date: April 21, 2011Inventors: Paul Dudas, Sarah Sague, Merle M. Elloso, Francis Farrell
-
Publication number: 20110091377Abstract: The present invention relates to methods of determining melanoma status in a subject. The invention also relates to kits for determining melanoma status in a subject. The invention further relates to methods of identifying biomarkers and correlating biomarker expression to melanoma status or stage in a subject.Type: ApplicationFiled: May 12, 2008Publication date: April 21, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Rhoda Myra Alani, Ryu Byungwoo, Megan J. Stine
-
Publication number: 20110085973Abstract: The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein.Type: ApplicationFiled: March 18, 2009Publication date: April 14, 2011Inventors: Kuo-Jang Kao, Andrew T. Huang
-
Publication number: 20110085970Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to B7H4 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided, immunoconjugates, including antibody-drug conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for treating cancer.Type: ApplicationFiled: November 26, 2008Publication date: April 14, 2011Inventors: Jonathan A. Terrett, Josephine M. Cardarelli, Chetana Rao-Naik, Bingliang Chen, David J. King
-
Publication number: 20110085971Abstract: The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes.Type: ApplicationFiled: October 15, 2010Publication date: April 14, 2011Inventors: Dan A. Buzatu, Jon G. Wilkes, Dwight Miller, Jerry A. Darsey, Tom Heinze, Alex Birls, Richard Beger
-
Publication number: 20110085972Abstract: The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes.Type: ApplicationFiled: October 15, 2010Publication date: April 14, 2011Inventors: Dan A. Buzatu, Jon G. Wilkes, Dwight Miller, Jerry A. Darsey, Tom Heinze, Alex Birts, Richard Beger
-
Publication number: 20110081292Abstract: Disclosed are methods of treating viral hepatitis including administering an effective amount of an early activation molecule agonist, antagonist or depletor, to the subject. Human monoclonal antibodies specific to the early activation molecules, and methods of use, are also disclosed.Type: ApplicationFiled: November 11, 2010Publication date: April 7, 2011Inventors: Francisco Sanchez-Madrid, Carlos-Martinez Alonso, David Sancho Madrid, Pablo Engel Rocamora, Enric Esplugues Artola, Javier Vega Ramos, Pilar Lauzurica Gómez
-
Publication number: 20110076232Abstract: The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to amplified epidermal growth factor receptor (EGFR) and to the de2-7 EGFR truncation of the EGFR. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof.Type: ApplicationFiled: September 24, 2010Publication date: March 31, 2011Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCHInventors: Lloyd J. Old, Terrance Grant Johns, Con Panousis, Andrew Mark Scott, Christoph Renner, Achim Jungbluth, Elizabeth Stockert, Vincent Peter Collins, Webster K. Cavenee, Huei-Jen Su Huang, Antony Wilks Burgess, Edouard Collins Nice, Anne Murray, George Mark, Gerd Ritter
-
Publication number: 20110070156Abstract: Described herein are compositions and methods of use of radionuclide-antibody conjugates (for RAIT) and drug-antibody conjugates (ADC). The combination of RAIT and ADC was more efficacious than either RAIT alone, ADC alone, or the sum of effects of RAIT and ADC. The unexpected synergy resulted in decreased tumor growth rate and increased survival, with a high incidence of tumor-free survival in Capan-1 human pancreatic cancer xenografts in nude mice.Type: ApplicationFiled: December 1, 2010Publication date: March 24, 2011Applicant: IMMUNOMEDICS, INC.Inventors: Serengulam V. Govindan, David M. Goldenberg
-
Publication number: 20110064654Abstract: The present invention relates to novel antibodies and their use for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof. The present invention also relates to novel pharmaceutical compositions for the treatment of prostate cancer. Furthermore the present invention relates to assay systems and kits for detecting, imaging, staging, treating and monitoring of prostate cancer, and/or metastasis thereof.Type: ApplicationFiled: September 10, 2010Publication date: March 17, 2011Applicant: Proscan Rx Pharma Inc.Inventors: Claudio Cuello, Uri Saragovi, Pierre Du Ruisseau, Phil Gold, Nicole Bernard, Serge Moffett
-
Publication number: 20110064653Abstract: The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR sequences DYYMS (SEQ ID NO:4); FIANKANGHTTDYSPSVKG (SEQ ID NO:5); and DMGIRWNFDV (SEQ ID NO:6). The Class I anti-CEA antibodies or fragments are useful for treating diseases, such as cancer, wherein the diseased cells express CEACAM5 and/or CEACAM6 antigens. The Class I anti-CEA antibodies or fragments are also of use for interfering with specific processes, such as metastasis, invasiveness and/or adhesion of cancer cells, or for enhancing sensitivity of cancer cells to cytotoxic agents and have favorable effects on the survival of subjects with cancer.Type: ApplicationFiled: July 29, 2010Publication date: March 17, 2011Applicant: IMMUNOMEDICS, INC.Inventors: Hans J. Hansen, Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 7906121Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.Type: GrantFiled: April 3, 2009Date of Patent: March 15, 2011Assignee: IBC Pharmaceuticals, Inc.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20110059011Abstract: The present invention relates to the diagnosis and treatment of leukemia and cardiovascular disease, as well as the detection of diseased and damaged tissue. More particularly, the present invention provides methods for targeting calcitonin receptor expressing cells for the diagnosis and treatment of leukemia or cardiovascular disease, and for stimulating wound healing. The invention also provides antibodies to calcitonin receptor expressing cells and methods of imaging or localising cells expressing calcitonin receptor. Also provided is an enriched population of CTR+VCD34+ cells.Type: ApplicationFiled: September 26, 2008Publication date: March 10, 2011Inventors: Peter John Wookey, Anthony Zulli
-
Publication number: 20110059012Abstract: This invention provides, among other things, methods for the identification and isolation of viable putative long-lived antigen-specific memory CD8+ T cell subsets (CMhi and EMhi) with high surface expression of CD161 and/or IL-18R? and the capacity to rapidly efflux the fluorescent dye Rh123.Type: ApplicationFiled: January 28, 2009Publication date: March 10, 2011Applicant: Fred Hutchinson Cancer Research CenterInventors: Cameron J Turtle, Stanley R. Riddell
-
Publication number: 20110060605Abstract: The present disclosure relates generally to methods and materials for determining the responsiveness of a subject with a disease or disorder to an inhibitor of a receptor tyrosine kinase including, for example, IGF1R. Such methods may comprise obtaining a biological sample from the subject, assaying the biological sample for one or more PIK3CA mutations, determining if one or more PIK3CA mutations are present in the biological sample, and employing the determination of one or more PIK3CA mutations in the biological sample to predict responsiveness of the subject to the receptor tyrosine kinase inhibitor.Type: ApplicationFiled: September 9, 2010Publication date: March 10, 2011Applicant: QUINTILES TRANSNATIONAL CORP.Inventor: Sarah Bacus
-
Publication number: 20110059013Abstract: The invention provides anti-Robo4 antibodies, and compositions comprising the antibodies and methods of using these antibodies, including diagnostic and therapeutic methods.Type: ApplicationFiled: September 22, 2010Publication date: March 10, 2011Applicant: Genentech, Inc.Inventors: Alexander W. Koch, Scott Stawicki, Yan Wu, Richard Carano, Franklin V. Peale, JR., Ryan J. Watts
-
Publication number: 20110052489Abstract: The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence.Type: ApplicationFiled: October 19, 2010Publication date: March 3, 2011Applicant: IMMUNOMEDICS, INC.Inventors: Hans J. Hansen, Zhengxing Qu, David M. Goldenberg
-
Publication number: 20110052488Abstract: Methods of identifying, diagnosing, and prognosing rheumatoid arthritis are provided, as well as methods of treating rheumatoid arthritis. Also provided are methods for identifying effective rheumatoid arthritis therapeutic agents and predicting responsiveness to rheumatoid arthritis therapeutic agents.Type: ApplicationFiled: September 2, 2010Publication date: March 3, 2011Applicant: Genentech, Inc.Inventors: Glynn Dennis, JR., Flavius Martin, Michael J. Townsend
-
Patent number: 7897139Abstract: The present invention is directed to the diagnosis and treatment of diseases, preferably the inhibition of tumor growth and its progression to metastatic sites, through the inhibition of the production of PTHrP, its isoforms or PTHrP signalling. The present invention is also directed to methods of inhibiting the PTHrP1-173 isoform through antagonists thereof, including monoclonal antibodies and siRNA directed there against. The invention may be applicable to many disease states, including but not limited to several types of cancer (such as breast, lung, prostate, melanoma and squamous) expressing PTHrP and its isoforms, alone or in combination with other therapeutic agents.Type: GrantFiled: August 17, 2007Date of Patent: March 1, 2011Assignee: Biochrom Pharma, Inc.Inventors: Richard Kremer, Dao Chao Huang
-
Publication number: 20110044896Abstract: The present invention relates to an antibody or a fragment thereof which is capable of binding to a Frizzled homologue 10 (FZD10) protein, such as a mouse monoclonal antibody, a chimeric antibody and a humanized antibody. Also, the present invention relates to a method for treating and/or preventing FZD10-associated disease; a method for diagnosis or prognosis of FZD10-associated disease; and a method for in vivo imaging of FZD10 in a subject.Type: ApplicationFiled: August 24, 2006Publication date: February 24, 2011Inventors: Yusuke Nakamura, Toyomasa Katagiri
-
Patent number: 7892554Abstract: This invention provides novel erbB2-binding internalizing antibodies. The antibodies, designated F5 and C1, specifically bind to c-erbB2 antigen and, upon binding, are readily internalized into the cell bearing the c-erbB2 marker. Chimeric molecules comprising the F5 and/or C1 antibodies attached to one or more effector molecules are also provided.Type: GrantFiled: June 1, 2007Date of Patent: February 22, 2011Assignee: The Regents of the University of CaliforniaInventors: James D. Marks, Marie Alix Poul
-
Publication number: 20110038790Abstract: Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.Type: ApplicationFiled: December 29, 2008Publication date: February 17, 2011Inventors: Dale B. Schenk, Peter A. Seubert, Johathan Wall, Jose Saldanhe
-
Publication number: 20110038791Abstract: In some aspects, the invention provides a method of inhibiting interaction of Six1 with Eya2 comprising contacting a cell expressing Six1 and Eya2 with an agent that inhibits binding of Six1 to Eya2 or an agent that inhibits the phostphatase activity of Eya2 on Six1. In other apsects, the invention provides a method of treating cancer in a subject comprising administering to said subject an effective amount of an agent that inhibits Six1 interaction with Eya2 or an agent that inhibits the phostphatase activity of Eya2 on Six1. In some embodiments, the invention further provides for the administration of a second cancer therapy to the patient. In still further aspects, the invention provides a method of identifying a candidate anti-cancer agent. The candidate inhibitor may be a nucleic acid, a protein, a peptide or a small molecule.Type: ApplicationFiled: February 25, 2009Publication date: February 17, 2011Inventors: Heide L. Ford, Rui Zhao, Aaron Patrick
-
Publication number: 20110033378Abstract: Cysteine engineered antibodies useful for the site-specific conjugation to a variety of agents are provided. Methods for the design, preparation, screening, selection and use of such antibodies are also provided.Type: ApplicationFiled: January 16, 2009Publication date: February 10, 2011Applicant: Medlmmune, LLC.Inventors: Nazzareno Dimasi, Changshou Gao, Herren Wu
-
Publication number: 20110027174Abstract: The present invention provides a novel approach to cancer therapy and diagnostics that utilizes nanotubes and other similar nanostructures as both an indirect source of radiation therapy (BNCT), and as delivery vehicles for other types of radio- and chemo-therapeutic materials, as well as imaging agents for diagnostic purposes.Type: ApplicationFiled: October 15, 2010Publication date: February 3, 2011Inventors: Dan A. Buzatu, Jon G. Wilkes, Dwight Miller, Jerry A. Darsey, Tom Heinze, Alex Birls, Richard Beger
-
Publication number: 20110027173Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer, for monitoring the effectiveness of bladder cancer, breast cancer, colorectal cancer, head and neck cancer, kidney cancer, lung cancer or pancreatic cancer treatment, and for drug development based on Ephrin Type-A Receptor 10 Protein.Type: ApplicationFiled: December 24, 2008Publication date: February 3, 2011Applicant: OXFORD BIOTHERAPEUTICS LTDInventors: Christian Rohlff, Alasdair Stamps
-
Publication number: 20110020222Abstract: Novel compounds, compositions and methods comprising modified antibodies are provided. In preferred embodiments the disclosed modified antibodies comprise antibodies having one or more of the constant region domains altered or deleted to afford beneficial physiological properties such as enhanced target localization and rapid blood clearance. The disclosed compounds are particularly useful for the treatment of neoplastic disorders in myelosuppressed patients.Type: ApplicationFiled: May 28, 2010Publication date: January 27, 2011Applicant: BIOGEN IDEC MA Inc.Inventors: Gary R. Braslawsky, Nabil Hanna, Paul Chinn